Preventive tuberculosis treatment effect on QuantiFERON TB-Gold in-tube testing in a high tuberculosis-endemic country: A clinical trial

Abstract

Background: Whether T-cell interferon-g responses to Mycobacterium tuberculosis-specific antigens can be influenced by tuberculosis preventive treatment in a high-endemic country is uncertain. Methods: In this prospective, open-label, controlled study, 513 individuals with silicosis were randomly selected for TB preventive treatment with rifapentine and isoniazid or for observation. QuantiFERON-TB Gold in-tube (QFT-GIT) assay was used to measure IFN-g response to M. tuberculosis antigens at baseline (T0) and at 6 (T1) and 33 (T2) months after completion of therapy. Results: A total of 220 subjects were included in the final analysis: 105 and 115 in the prevention and observation arms, respectively. The proportions of QFT-GIT reversion from baseline to T1 were similar in the prevention and observation arms (18.4% vs 12.8%, P = 0.566). However, reversion from baseline to T2 was more frequent in the prevention arm than in the observation arm, but the difference was not significant (24.2% vs 6.3%, P = 0.881). No significant difference was observed in the quantitative responses of QFT-GIT between the two arms during follow-up at T1 (P = 0.648) and T2 (P = 0.918). Conclusions: Preventive tuberculosis treatment has no effect on interferon-g responses measured by serial QFT-GIT assays in a high tuberculosis-endemic country. Clinical Trials Registration: http://www.clinicaltrials.gov NCT02430259.

First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting

“…So far, WHO has endorsed three IGRA tests, T-SPOT 1 .TB (Oxford Immunotec, Abingdon, UK), Beijing Wantai's TBIGRA (Wantai), and QuantiFERON 1 -TB Gold Plus (QFT, QIAGEN, Hilden, Germany), able to measure IFN-γ released by both CD4 and CD8 T cells [23][24][25][26][27][28].…”

A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab

“…After controlling the probable confounders involving baseline TB-IGRA, the pretreatment prophylactic therapy did not influence the elevating TB-IGRA value, and there was no significant increase in the ATB or NTB group. We considered that the increasing tendency of TB-IGRA values in the current study might be correlated with the high epidemic background rather than receiving prophylactic treatment based on previous evidence [ 22 ]. Furthermore, combining the results of the TB status mentioned, we found that none of the patients developed active TB despite varying TB-IGRA values.…”

Comparison of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold-Plus in the Diagnosis of Mycobacterium tuberculosis Infections in Immunocompromised Patients: a Real-World Study

“…However, IGRA does not measure the infection itself; it is a surrogate immunological test which cannot distinguish between active TB and LTBI. Notably, preventive TB treatment has no effect on the results of a QuantiFERON-TB Gold In-Tube (QFT-GIT) assay, a type of IGRA, when evaluated in a highly TB-endemic country ( 10 ).…”